At SIU Medicine, our researchers perform clinical trials and research studies with the aim of translating findings into new, more effective treatments.
PROSPECT: This is an observational study and is designed to describe the clinical outcomes and the burden of disease in PD patients with motor fluctuations not adequately controlled by current PD medications.
I5T-MC-AACI: Alzheimer’s is a disease that attacks the brain, causing problems with memory, thinking, and behavior. Symptoms usually develop slowly and get worse over time, eventually making daily tasks impossible. Although we don’t know the exact cause, researchers found out that the two proteins called tau and amyloid are building up in brains of people with Alzheimer’s disease even before they have any symptoms.
Lauriet: The purpose of this study is to compare the effects, good or bad, of MTAU9937A versus placebo on patients with moderate AD. In this study, you will get either MTAU9937A or placebo. MTAU9937A is an experimental drug, which means health authorities such as the Food and Drug Administration (FDA) have not approved it for the treatment of moderate AD or other conditions. MTAU9937A is in early development and has been previously studied in healthy subjects and people with milder forms of Alzheimer’s disease.
POST GRAD: The purpose of this study is to compare the effects, good or bad, of long term gantenerumab on subjects with prodromal or mild Alzheimer's disease.
